Generative Artificial Intelligence (AI) In Drug Discovery Market Report 2026

Generative Artificial Intelligence (AI) In Drug Discovery Market Overview

• Generative Artificial Intelligence (AI) In Drug Discovery market size has reached to $0.25 billion in 2025 • Expected to grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 27% • Growth Driver: Rising Clinical Trials on the Generative AI in Drug Discovery Market • Market Trend: Advanced AI Solutions To Revolutionize Drug Discovery And Precision Medicine • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Generative Artificial Intelligence (AI) In Drug Discovery Market?

Generative AI in drug discovery involves using advanced machine learning, especially generative models, to create and identify new pharmaceutical compounds. These AI systems analyze extensive data, including chemical properties, biological activity, and existing drug information to predict and generate novel molecules with potential therapeutic benefits. The primary aim of generative AI in drug discovery is to accelerate the creation and identification of novel pharmaceutical compounds with potential therapeutic effects, optimizing the drug development process by leveraging extensive data to predict and generate new molecules efficiently. The main types of generative artificial intelligence (AI) in drug discovery are small molecule and large molecule. The small molecules are drugs that are chemically synthesized and typically have a low molecular weight. The technologies include deep learning, machine learning, reinforcement learning, molecular docking, and quantum computing are used by various end-users including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), and others.

What Is The Generative Artificial Intelligence (AI) In Drug Discovery Market Growth Forecast?

The generative artificial intelligence (ai) in drug discovery market size is expected to see exponential growth in the next few years. It will grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 27.0%. The growth in the forecast period can be attributed to integration of generative models in pipelines, demand for faster drug discovery, expansion of biologics optimization, collaboration between ai firms and pharma, reduced time-to-market. Major trends in the forecast period include rising adoption of AI-driven molecule generation, increased use of deep learning in drug design, expansion of small molecule discovery applications, growing integration of ai in lead optimization, accelerated early-stage drug development.

Global Generative Artificial Intelligence (AI) In Drug Discovery Market Segmentation

1) By Type: Small Molecule, Large Molecule 2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing 3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users Subsegments: 1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction 2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization

What Is The Driver Of The Generative Artificial Intelligence (AI) In Drug Discovery Market?

The rising number of clinical trials is expected to propel the growth of generative AI in the drug discovery market. Clinical trials involve human volunteers and assess the safety and effectiveness of new medical treatments or procedures, aiming to gather scientific data on their suitability for human use. The rising number of clinical trials is primarily attributed to advancements in medical research, increased disease burden, regulatory changes, globalization of clinical research, patient advocacy and awareness, industry competition, technological advancements, and funding opportunities. Clinical trial data fuels generative AI models, expediting drug discovery by predicting interactions and designing compounds. This synergy enables personalized medicine, optimizes treatment efficacy, improves patient outcomes, and revolutionizes the pharmaceutical landscape. For instance, in January 2025, according to Pharmaceutical Technology, a UK-based business news and media company, there are 3,213 trials planned to start this year, including 823 in Phase I and 1,102 in Phase II. As with 2024, oncology is expected to remain the top therapeutic area, accounting for 946 trials, followed by the central nervous system with 686 trials, then cardiovascular some way behind with 258 trials. Therefore, the rising number of clinical trials is driving the growth of generative AI in the drug discovery market.

Key Players In The Global Generative Artificial Intelligence (AI) In Drug Discovery Market

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc

Global Generative Artificial Intelligence (AI) In Drug Discovery Market Trends and Insights

Major companies operating in the generative AI in the drug discovery market are developing advanced AI-powered tools to accelerate drug discovery processes. AI-powered tools accelerate drug development by streamlining drug discovery, design, and clinical trials through predictive analytics and machine learning. They enhance efficiency in target identification and compound screening such as virtual screening using AI, preclinical development, regulatory compliance, and manufacturing processes. For instance, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, introduced two innovative AI-driven solutions. These solutions, the Target and Lead Identification Suite and the Multiomics Suite are designed to improve drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite helps researchers understand amino acid functions and predict protein structures, while the Multiomics Suite speeds up the analysis and understanding of genomic data, simplifying the development of personalized treatments.

What Are Latest Mergers And Acquisitions In The Generative Artificial Intelligence (AI) In Drug Discovery Market?

In May 2023, Recursion Pharmaceuticals, a US-based clinical-stage TechBio company, acquired Cyclica and Valence for $40 million and $47.5 million. The acquisitions of Cyclica and Valence by Recursion have significantly enhanced its drug discovery capabilities through advanced technologies. This positions Recursion as a leading hub for top-tier professionals in ML and AI, poised to innovate and drive the future of drug discovery. Cyclica Inc. is a Canada-based biotechnology company specializing in data-driven drug discovery, biophysics, and artificial intelligence to develop predictive analytics software, and Valence Labs is a Canada-based AI-driven research organization that focuses on advancing the frontier of AI in drug discovery.

Regional Outlook

North America was the largest region in the generative AI in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Generative Artificial Intelligence (AI) In Drug Discovery Market?

The generative AI in drug discovery market includes revenues earned by entities by providing services such as molecule generation, optimization, virtual screening, predictive modeling, de novo drug design, and consulting support. The market value includes the value of related goods sold by the service provider or included within the service offering. The generative AI in drug discovery market also includes sales of quantum computers, high-performance computing (HPC) clusters, tensor processing units, graphics processing units, and preclinical development tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Generative Artificial Intelligence (AI) In Drug Discovery Market Report 2026?

The generative artificial intelligence (ai) in drug discovery market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the generative artificial intelligence (ai) in drug discovery industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.